Abstract:The transcription factor MYC and its related family members MYCN and MYCL have been implicated in the etiology of a wide spectrum of human cancers. Compared to other oncoproteins, such as RAS or SRC, MYC is unique because its protein coding region is rarely mutated. Instead, MYC's oncogenic properties are unleashed by regulatory mutations leading to unconstrained high levels of expression. Under both normal and pathological conditions MYC regulates multiple aspects of cellular physiology including proliferation, differentiation, apoptosis, growth and metabolism by controlling the expression of thousands of genes. How a single transcription factor exerts such broad effects remains a fascinating puzzle. Notably, MYC is part of a network of bHLHLZ proteins centered on the MYC heterodimeric partner MAX and its counterpart, the MAX-like protein MLX. This network includes MXD1-4, MNT, MGA, MONDOA and MONDOB proteins. With some exceptions, MXD proteins have been functionally linked to cell cycle arrest and differentiation, while MONDO proteins control cellular metabolism. Although the temporal expression patterns of many of these proteins can differ markedly they are frequently expressed simultaneously in the same cellular context, and potentially bind to the same, or similar DNA consensus sequence. Here we review the activities and interactions among these proteins and propose that the broad spectrum of phenotypes elicited by MYC deregulation is intimately connected to the functions and regulation of the other network members. Furthermore, we provide a meta-analysis of TCGA data suggesting that the coordinate regulation of the network is important in MYC driven tumorigenesis. This article is part of a Special Issue entitled: Myc proteins in cell biology and pathology.

Exploring Myc puzzle: Insights into cancer, stem cell biology, and PPI networks

Ire1 Alpha Rnase-Dependent Lipid Homeostasis Promotes Survival In Myc-Transformed Cancers

Myc beyond Cancer: Regulation of Mammalian Tissue Regeneration

MYC on the Path to Cancer

Targeting Myc Interacting Proteins As a Winding Path in Cancer Therapy

Targeting oncogenic Myc as a strategy for cancer treatment

MYC as a Multifaceted Regulator of Tumor Microenvironment Leading to Metastasis

MYC Oncogene: A Druggable Target for Treating Cancers with Natural Products

Alternative approaches to target Myc for cancer treatment

Insights into the Links between MYC and 3D Chromatin Structure and Epigenetics Regulation: Implications for Cancer Therapy

The long journey to bring a Myc inhibitor to the clinic

MYC: there is more to it than cancer

Targeting Myc-driven stress addiction in colorectal cancer

MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies

The MYC oncogene — the grand orchestrator of cancer growth and immune evasion

Molecular Pathways: Targeting MYC-induced Metabolic Reprogramming and Oncogenic Stress in Cancer.

Identification and analysis of the regulatory network of Myc and microRNAs from high-throughput experimental data

MYC protein interactors in gene transcription and cancer

MYC dysfunction modulates stemness and tumorigenesis in breast cancer

Functional interactions among members of the MAX and MLX transcriptional network during oncogenesis

Regulation of Normal and Neoplastic Proliferation and Metabolism by the Extended Myc Network